Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
ConditionPoor Responders in IVF
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-54
SponsorBarzilai Medical Center
About this trial
Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.
Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.
The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Poor response according to "Bologna criteria"
Disqualifiers
Allergy to metoclopramide
Prolactinemia
Women treated with dopamine agonists
Trial design
Design model
Parallel
Treatments tested in this trial
Metoclopramide
DrugMetoclopramide 10 mg BID
Placebo Oral Tablet
DrugPlacebo 10 mg BID
Treatment groups
60 Participants
are divided into 2 treatment groupsGroup A: Metoclopramide 10 mg BIDExperimental treatment 1 intervention
Group B: Placebo 10 mg BIDPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Number of oocytes
Number of oocytes
Time frame
Approximately 5 weeks from first dose of study drugSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov